Influenza – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Influenza Emerging Therapy and TPP Insights

Thelansis’s “Influenza Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Influenza Overview

Influenza is an acute respiratory viral infection characterized by continual antigenic evolution, driving recurrent seasonal epidemics and creating persistent pandemic risk. Seasonal vaccination remains the cornerstone of prevention, but circulating viruses can continue to drift after strain selection, requiring annual formulation updates; for 2026–27, all three U.S. vaccine components were updated. Antivirals including oseltamivir and baloxavir remain effective treatment options when used appropriately, with greatest benefit from early initiation, although treatment remains particularly time-sensitive in uncomplicated outpatient disease. The vaccine landscape is now entering a new phase: on August 5, 2026, the FDA approved MFLUSIVA, Moderna’s mRNA influenza vaccine, for adults aged 50 years and older, providing the first commercial validation of an mRNA seasonal influenza platform in the United States. Its platform can accommodate seasonal strain updates without redesigning the underlying delivery system. In parallel, universal and broadly protective vaccines targeting conserved influenza antigens remain an important research frontier. For stakeholders, influenza innovation is shifting from simply improving annual strain matching toward rapidly updateable platforms, broader immunity, and potentially more durable protection across seasons and viral subtypes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)